Please select the option that best describes you:
What is your preferred first line treatment approach for a patient with PDL-1 high (>50%) NSCLC presenting with CNS mets?
If a patient is asymptomatic at presentation, how do you incorporate local treatment options (RT/surgery) and when?
Answer from: Medical Oncologist at Academic Institution
The treatment decision and sequencing in patients with brain metastasis from non-oligometastatic NSCLC with high PD-L1 expression and no traditional actionable genomic alterations depend on size and location of brain mets as well as associated symptoms.Based on data from several prospective and retr...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Pembrolizumab, if asymptomatic. SBRT in addition, if symptomatic.